Russell Investments Group Ltd. Acquires 22,196 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Russell Investments Group Ltd. increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 73.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,541 shares of the biotechnology company's stock after acquiring an additional 22,196 shares during the quarter. Russell Investments Group Ltd. owned about 0.07% of Axon Enterprise worth $13,575,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. boosted its stake in Axon Enterprise by 8.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 7,716 shares of the biotechnology company's stock valued at $1,535,000 after acquiring an additional 630 shares during the last quarter. Stratos Wealth Partners LTD. grew its stake in shares of Axon Enterprise by 18.3% during the third quarter. Stratos Wealth Partners LTD. now owns 4,960 shares of the biotechnology company's stock worth $987,000 after purchasing an additional 766 shares during the period. Bank of New York Mellon Corp increased its holdings in Axon Enterprise by 28.3% in the third quarter. Bank of New York Mellon Corp now owns 726,400 shares of the biotechnology company's stock valued at $144,546,000 after purchasing an additional 160,359 shares during the last quarter. Forsta AP Fonden lifted its stake in Axon Enterprise by 18.2% in the third quarter. Forsta AP Fonden now owns 32,500 shares of the biotechnology company's stock valued at $6,467,000 after buying an additional 5,000 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in Axon Enterprise by 2.3% in the third quarter. Mackenzie Financial Corp now owns 6,292 shares of the biotechnology company's stock valued at $1,208,000 after buying an additional 141 shares during the period. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Up 0.6 %

Shares of AXON stock traded up $1.80 on Friday, hitting $318.55. 279,175 shares of the stock were exchanged, compared to its average volume of 468,981. The business has a 50-day moving average of $308.83 and a 200 day moving average of $265.28. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87. The firm has a market capitalization of $24.04 billion, a P/E ratio of 138.50 and a beta of 0.91. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.29. The company had revenue of $432.14 million during the quarter, compared to analysts' expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Equities analysts anticipate that Axon Enterprise, Inc. will post 2.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com cut Axon Enterprise from a "buy" rating to a "hold" rating in a research note on Thursday, March 14th. TheStreet lowered shares of Axon Enterprise from a "b" rating to a "c+" rating in a report on Tuesday, February 27th. Barclays boosted their price target on shares of Axon Enterprise from $296.00 to $308.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Argus assumed coverage on Axon Enterprise in a research note on Wednesday, March 13th. They set a "buy" rating and a $380.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, April 24th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $323.09.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.